T 44 1925 607101 E infoarcisbiocom W wwwarcisbiocom Arcis solutions for saliva sample prep Simplified prep for lateral flow and PCR analysis Move to less invasive rapidtesting Arcis ID: 1044606
Download Presentation The PPT/PDF document "Arcis Biotechnology Limited" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Arcis Biotechnology LimitedT: +44 1925 607101E: info@arcisbio.comW: www.arcisbio.com Arcis solutions for saliva sample prepSimplified prep for lateral flow and PCR analysis
2. Move to less invasive rapid-testingArcis BioTechnology - Commercial in confidenceConversion of lateral flow from swab or blood to salivaNo lances, swabs, or technician-assisted sample collectionLimitations of swab and blood-based testing:Sampling Requires healthcare professionalsPatient discomfort with invasive samplingCost and availability of lancets and swabsLimits expansion of test programsSaliva enables:Avoidance of assisted sample collection No patient discomfort Elimination of lancets and swabsRapid expansion of test programs25/11/20202Arcis enables:
3. Simplify protein preparation+Antigen/Antibody preparation for immunoassayReplace loading buffer to enable saliva●Effective protein stabilization●Non-hazardous chemistry Arcis Buffer
4. Convert blood lateral flow assays to saliva with enhanced sensitivityConverted assay shows greater sensitivity than original format without affecting specificityResults from 30 positive samples (Left) and 30 negative samples (Right) analysed with Leccurate SARS-COV-2 Antibody LF Test. Blood samples tested using kit manufacturers instructions. Saliva samples tested by replacing manufacturers sample buffer with Arcis reagent. Results confirmed by RT-qPCR performed using Applied Biosystems TaqPath COVID-19 CE-IVD RT-PCR Kit.Assay SensitivityAssay SpecificityArcis BioTechnology - Commercial in confidence4
5. Antibody detection with Arcis mirrors immune response‡ PPA determined relative to RT Q-PCR performed using Applied Biosystems TaqPath COVID-19 CE-IVD RT-PCR Kit100% detection concordance with RT Q-PCR up to 20 days post diagnosis (31 positive samples)Tracking of IgM and IgG response with Leccurate Blood lateral flow test converted to Saliva with Arcis reagentDays Post PCR0-5 days6-10 days11-20 days21-30 days>30 daysAntibodyIgMIgGIgMIgGIgMIgGIgMIgGIgMIgGNumber of Samples6615151010771313Positive Samples6315159103603PPA%10050100100901004386023PPA% combined‡ 1001001008623Arcis BioTechnology - Commercial in confidence5
6. Conversion of Antigen test from swab to Saliva (Proof of Concept) Fluorecare™ SARS-CoV-2 Spike Protein Test Kit converted to Saliva samples with Arcis Immunoassay reagentNo of samplesRTqPCR*Rapid Saliva Protein Test (SARS-CoV-2 Spike Protein)Concordance66 positive6 positive100%*Applied Biosystems TaqPath COVID-19 CE-IVD RT-PCR KitPreliminary data indicates successful conversion of swab lateral flow device to saliva with Arcis Immunoassay ReagentArcis BioTechnology - Commercial in confidence6
7. Arcis Biotechnology founded 2010Patented chemistryScalable manufacturing facilitySummary of ability to prep saliva for antigen and antibody testing 7Arcis results indicate ability to: Convert lateral flow rapid tests from swab or blood to salivaLyse virus without denaturing proteinsNo sacrifice of sensitivitySeeking partner for advancing the application